Leukemia Diagnosis and Treatment Center
白血病诊疗中心 · Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
The Leukemia Diagnosis and Treatment Center focuses on the clinical care and research of leukemia. The team uses risk-stratified treatment based on prognostic factors to improve outcomes for acute leukemia. Protocols include homoharringtonine combined with anthracyclines, and intermediate-dose cytarabine for acute myeloid leukemia. These approaches have been adopted into national clinical guidelines. The center also develops CD19 CAR-T cell therapy (HI19a-4-1BB-ζ). An Phase I trial for this therapy began recruiting in January 2020 and has completed dose escalation. A Phase II trial was expected to start in early 2021. Research findings have been published in journals such as Clinical Cancer Research and Haematologica.
Conditions and treatments
- Diagnosis and treatment of leukemia
- Risk-stratified therapy for acute leukemia
- Treatment with homoharringtonine and anthracyclines
- Intermediate-dose cytarabine induction for acute myeloid leukemia
- CD19 CAR-T cell therapy (HI19a-4-1BB-ζ) clinical trials
Key facts
- The department has 92 open beds.
- The medical team includes 19 doctors and 42 nursing staff.
- Phase I clinical trials for CD19 CAR-T therapy began recruiting in January 2020.
Rewritten in English from the department's own description on a public doctor-listing platform. Claims such as "leading" are the hospital's own.
| Specialty | Hematologic Oncology |
|---|---|
| Doctors listed | 17 |
| Chief physicians | — |
We are an independent coordination service, not part of this hospital. Names and titles change; the hospital's website is the final word. How we build this directory.
Need a specialist's opinion?
Send your records and question. We find a specialist in the right field who reviews your case and tells you what they recommend.
Contact us